

PDF version

□ □ □ □ □   □ □ □ □ ¹ □ □ □ □ □ □ □ □   □ □ □ □ □ □ □ □   ²

Direct-to-consumer advertising for pharmaceuticals in Jordan from a gender perspective

ABSTRACT This study aimed to investigate the extent to which direct-to-consumer advertising (DTCA) for pharmaceuticals is disseminated in Jordan and to identify subsequent gender differences. The study was conducted on two samples: 1) patients (drug consumers) attending Jordan University Hospital, and 2) physicians working at the hospital (prescribers). A questionnaire was distributed to male and female patients (n=550), and based on its results a second questionnaire was designed and distributed to male and female physicians (n=200). The response rate was 93% for patients and 72% for physicians. Although the Jordanian Drug and Pharmacy Law prohibits the public promotion of medicines, consumers remain exposed to pharmaceutical advertising. The top ten drug classes advertised directly to consumers in Jordan included prescription-only drugs. Approximately 45% of the two samples agreed that women were more likely to be targeted by DTCA, while only 2% of them believed that men are more likely to be targeted. However, there was no statistically significant gender difference in attitudes towards pharmaceutical DTCA and tools used.

00000000000000000000 0000000000 00000000000 000000000 000 000 00000000 000 00000000 000 0000 :
 0000 000000 00 00 000000 0000 000000 00000000 00000000 00000000 00 0000000000 0000000
 00 (00000000 000000000000) 0000000 (1 :000 0000000 000 00000000 0000000 000 .0000000000
 000000 000000) 0000 0000000000 00 0000000000 00000000 (2 0000000000 00000000 0000000 0000000
 000000 000 0000000 0(550 000000) 00000000 0000000 0000000 000 00000000 0000000 000 .(0000000
 0000000 0000000000 0000000 00 00000000 000000 000 0000 00000000 000000 000000000000 000
 00 72% 00000000 00000 00 93% 00000000 000000000000 0000 0000 000 .(200 000000) 000000
 000000 000000000 000000 00000 00000000 0000000000 0000000 000000 00 000000 .00000000 00000
 00000 00 00000000 .000000000000 00000000000 0000000 000000 00000000 00000000000 000 0000000000
 000000 000 0000000 00 000000000000 00000000 000000000 0000000 00000 00000000 00 00000000 000
 000 00 000 0000000000 000000 00 45% 000000 00 000000 .0000 000000 000 0000000000 00
 0000000000 000000 00 000 2% 000000 00 00 000 00 00000000 00 00000 0000000 0000000 0000000000
 00000000 0000000 00 00000 000000 .0000000 00 00000 0000000 0000000 00000000000 00 00000000
 00000000 0000000000 00000000000 000 0000000000 00 000000 00000 00000000 000000 000 0000000
 .00000000000 00000000000 0000000000 0000000000

Publicité directe de médicaments auprès des consommateurs en Jordanie

vue sous l'angle de la différenciation hommes-femmes

RÉSUMÉ La présente étude visait à examiner la mesure dans laquelle la publicité directe de médicaments auprès des consommateurs est diffusée en Jordanie, et à identifier les différences hommes-femmes qui en découlaient. L'étude a été menée sur la base de deux échantillons : 1) les patients (consommateurs de médicaments) de l'hôpital de l'Université de Jordanie, et 2) les médecins exerçant à l'hôpital (prescripteurs). Un questionnaire a été distribué aux patients de sexe masculin et féminin (n=550), et sur la base des résultats de celui-ci, un deuxième questionnaire a été conçu pour les médecins de sexe masculin et féminin (n=200). Le taux de réponse était de 93 % pour les patients et de 72 % pour les médecins. Bien que la loi jordanienne sur les médicaments et les pharmacies interdise la promotion publique de médicaments, les consommateurs restent exposés à la publicité de produits pharmaceutiques. Le top dix des classes de médicaments faisant l'objet d'une publicité directe auprès des consommateurs en Jordanie incluait des médicaments disponibles uniquement sur ordonnance. Près de 45 % des deux échantillons ont convenu que les femmes étaient plus susceptibles d'être ciblées par la publicité directe auprès des consommateurs, et seulement 2 % pensaient que les hommes étaient plus susceptibles de l'être. Néanmoins, aucune différence hommes-femmes significative d'un point de vue statistique dans les attitudes à l'égard de la publicité directe de médicaments auprès des consommateurs et des outils utilisés n'a été observée.

¹المركز العربي لمكافحة الأمراض ومنع العدوى، جامعة الأردن، عمان، الأردن

²المركز الإفريقي لمكافحة الأمراض ومنع العدوى، جامعة القاهرة، القاهرة، مصر

:المركز الإفريقي لمكافحة الأمراض ومنع العدوى :المركز العربي لمكافحة الأمراض ومنع العدوى :المركز الإفريقي لمكافحة الأمراض ومنع العدوى

(i.abbadi@ju.edu.jo | ibrahimalabbadi@yahoo.com Received: 23/6/15; accepted: 06/06/16)

المركز العربي لمكافحة الأمراض ومنع العدوى

المركز العربي لمكافحة الأمراض ومنع العدوى، جامعة الأردن، عمان، الأردن

00000000 00000000 000000 -000000 00000000 00000000 000000 00000000 -00000000
00 0000000 000 00 000 0000000 00000000 00000000 000000 000000 00000000 000000 0000
0000000 000 00000 000000000 0(10) 00000 0000 000 00000000 000 00000 00000 000000
.000000 000000 00000 000 00000 00000000 0000000 000000

0000000 0000000 0000000000 0000000 0000000 0000000000 0000000 0000 0000000000 00000000000 00
 00 00000000 000000 00000000 0000 00000000 0000 0000 0000000000 00000000 0000000 0000000000
 0000000 0000000000 0000000 0000000 000000 00000000 0000000000 0000 0000000 000 000000
 0000 00 **86%** 000000 000 0000 0000000 000 **(10)** 0000000000 000 00 0000000000 000 0000000000
 00000000 0000000000 0000000 0000 0000000000 0000000000 00 000000 00 00000000 00000000000
 000 00000000 00000000 0000 – 00000 0000000 – 00000000 00 000000000000 000000 **35%** 0000
 00000000 0000000000 0000000000 00 00000000 **(11)** 00000000 00000000 000 00 00000000 000000
 000000 00000) 0000 00 0000000 00 00000000 0000000000 0000000 0000 0000000000 0000000000
 000000 00000000 000000 00000000 0000 0000 000000 00000000 0000000 0000 (0000000 000000000000
 0000 0000 00000000 000000 00000000 0000 **(12)** (0000 0000 000) 0000 0000 000000 000 0000
 0000000000 00 0000 000 000000 000000 000000 000000 000000 000000 000000000000 000000 00000000
(13) 0000000 0000000 0000 0000000 00000000 0000000 0000000 00000000 0000000 000000 0000000000
 0000000 0000 0000000000 00000000000 0000 0000000000 00 00000000 0000000 000000 0000 000 00000
 000 000 0000000 000000 000000 000000 000000 000000 0000 000000 00000 000 0000000 0000000000
 0000 0000000000 00000000000 000 00 000000 000 0000 00000000 0000000000 00 000 **(14)** 0000000000
 0000 000000 000000 00000 000 000 000000 00000000 00000000 0000000000 0000000000 0000000000
 000 00000000 000 0000000000 0000000000 00 00000000 00 00000 0000 000000 0000 000 0000000000
(15) 0000000000 000 000 00 0000000000 0000000

00000000 00000000 00000000 00 00000000 0000000000 0000000000 0000000000 0000000000 000000 0000
 0000000000 - 0000000000 00 00000000 0000 00000000 0000 000000000000 0000000000 000000 00 0000 0000
 000 0000 00000000 00 000 00000000 0000000000 00000000 00 0000 0 00000 00000 0000 - 0000000000 0000000000
 00000000 00000000 00 0000000000 00000000 000000 0000 0000 000000 000000 0000 0000 0 (4) 0000000000 0000 0000000000
 00000 00000000 000000000000 00000000 000000 0000 0000000000 0 (16) 00000 00000 00000000 00000000
 0000000000 0000000000 00000000 000000000000 0000 000000000000 00 00000000 0000000000 000000 000000000000
 0000000000 00 00000 .(17) 0000000000 0000000000 000000000000 0000 00000000 00000000 00000 0000000000
 0000 0000 00000000 00 0000000000 0000000000 0000 00 0000000000 0000 0000 0000000000 00 00000000000000
 0000000) 000000 000000 000000 00 0000 00000000 00000000 00000000 00000000 00 0000000000 000000000000 00000000
 000000000000 0000000000 000000 00000000 000000 000000 000000 000000 000000 0000000000 0000000000 00000000
 000000000000 0000000000 00000000 00000000 0000 0000 000000 0000000000 000000 (00000000
 000000000000 0000000000 00000000 00000000 0000 0000 000000 00000000 00 00000 00000 0000 0000000000
 .(18) 00000000 0000 0000 000000 00000000 0000 0000 0000000000 000000 0000 0000000000 00000 00000 000000

000 000000 000000 00000000 00000 0000000 000 000000 00000000 00000 00000 0000
0000000 00 00000000 000 00000000 000000 000 000 000 .0000000 000000000000 0000000000
0000000000 0000 00 000000 00000000 0000000000 0000000 000000 00000 0000000 00000000 0000000

[illegible]

000000 000000 00000000 000 0000 00 " 000000 00000000 00000 000000 0000 00 00 000
 000 00000 00000000 0000 00000000 00 000000 00000000 000 0000 000 0 "00000000 0000
 000000 000000 000000 000000000000 0000000000000000 0000 00 000000000000 000000000 00000000
 00000000 00 (00000000) 0000000 0000000 0000000 00000000 000 0000 00000 000 000000 00 00000000
 0000-000000 00000 000000000 0000000000 0000000000 0000 000 0000000 000000 000000 (18)
 00000000 000000 000000 0000 ."000000 0000" 00000000 0000 0000000000 0000 00000000000000
 0000000000 00 0000 000000000 0000000 000000 3-2 00000000 00000000 00000 000000 0000 00 00000 000
 0000000 000000 0000 000000 (8) 000000 00 000000000000 00000 000 00000000 000000 00000000000
 0000 00000 0000000000 000000000 00 00 00000 00000 00000000000 00000 00 000000 0000 .0000 00000000
 000000 00000000 00000000 000000 :0000 00000000 0000 00000000000 0000000 00000000 000000
 00000000 00 0000 0000 0000 00000000 000000 00000 00 00000000 000000 .00000000 0000000000
 00 0000 0000 0000000000 00000 00000000 000000000000 0000 00000 00 -000000000 00000 00000000
 0000000 00000 0000000000 000000 00000000000 00000 0000000000 00 00000000 0000 00000000 0000000
 000000000 00000000 000000000000 00000000000000 :0000 0000000 000000000 0000000 0000 000000 000000
 000000000 000000000 000000000 000000 00000 00000000 000000000 000 000000000 000000000000
 .0000000 0000 0000000 00 00000000 0000 00000 00000000 000000000

[illegible]

00 000000 000000 00 "000000 0000000000 00000000 00000000 00000 000000 00
 00 000 0000000000 00000000 000000 0000 00 "000000 00 000000 00000000 00 0000000000
 00 00000 "000000000 000000 "00 00000000 00 00000000 00 00000000 00 0000 00000000 000 0000
 000000000 0000000000 00000 000000 00000000000000 000000000 00 000000000 000 00000

000000 00 000000 0000 000000 000000 00 00000 .(1) 00000 000000000 0000000000 000000 00000000000
 00000 00000 000000000 0000000000 00000000 000000000 00 000000000 00000000 0000 00000000 0000 000000000
 0000 .(18) 0000000000 00000000000 000000000 00000 000000000 00000000 0000000000 0000000000 000000000
 00000000 000000 000000 00 00000 0000000000 00000000000 00 0000 0000 000000 00000000000 000000000 00
 000000000 00 000000 00000 00000 0000 00000000 000000000 000000 00000000000 00000000 000000000
 .(27) 0000000000 00000000000 000000000 00 0000 00000 0000000000

[illegible]

1000000

000000000 0000 00000000 000000000 00000 00 00 000 00000000 000 000000000 000 0000
 0000000 0000000 0000000 000000 0000000 00000000 00 000000 000000000 0000000 0000 000000000
 000 00 0000 0000000000 000000 00 0000 0000000000 00000000 00 00 0000000000 0000000
 00000000 000 000000 00000000 000 00000 00000 000 .00000000000 00000000 0000000 0000000
 000 00000000 00000000 00000000 00000 00 000000 00 0000000 000000000 00000000 0000000 0000000
 000000000 00000 000000 000000000 00000 00000 00000000000 000000000 000000 000 000000 000000
 000 000000000 00 000000000 000000000 0000 0000 00000000 000000000 00000000 000000 000000000
 000000 000000 00000000 000 00 0000000 000000 0000000000 00 00000000 00 000000000 00 000000 00
 .000000 000000 000000 00000000 0000000 000000 00000 000 00 000000000 000000000 000000 0000 0000

00 00000000 00000000 00 000000 00000 00000 000 00000000 00 0000000000 0000 0000 00
 0000 00000000 00000000 00 000 000000 000000 0000 00 00000000 0000 000000 0000 0000000000
 00000000 00 000000000 0000 00000 000000 00000000000000 00000000000 0000000 0000000 000000
 0000000 0000 000000 0000 0000000 00000000 0000000 00000 00 000 00000000 00000000 000000000
 000000 000000 0000 0000000 0000000 0000 0000000 0000000 00 00000 00 000000 000000 00000000
 0000000000 0000 0000 0000 000000000 .000000 00000000 00 00 000000 00 000000 000 000000 0000000
 0000 000000000000 0000000000 000000000 00 0000000 000000 000000000 0000 000000 00 0000000000 0000
 0000000 0000000000 0000 00000 .00000000 0000000 0000 00000000000 0000000 00000 000000 000000
 000000 00000 00000000 00000000 00000 0000000 0000000000 00000000000 0000000 0000000000 0000000
 0000 000000 0000 0000000000 .000000000 0000000000 0000000000 0000000 00000000 00 000000 00000000
 000000000 0000 00000000 00000 00 00000 000000000 0000000 00000000 0000000 00000000000 00000000
 0000000000 0000 000000000 000000 0000000000 00000000000 0000000000 00000000 00000000

.المراجع

17. Health Action International (HAI) (2001), Direct-to-Consumer Prescription Drug Advertising The European Commission's Proposals for Legislative Change: Amsterdam, The Netherlands.
18. Kempner, Joanna (2006), Gendering the migraine market: Do representations of illness matter? *Social Science & Medicine*, (63): 1986–1997.
19. Glass, Jennifer, Lanctôt, Krista, Herrmann, Nathan, Sproule, Beth and Busto, Usoa (2005), Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits, *BMJ*, (331): 1169-1173.
20. Wazaify, Mayyada, Al-Bsoul, Abla, Abu-Garbieh, Eman, Tahaine, Linda (2008), Societal perspectives on the role of community pharmacists and over-the-counter drugs in Jordan, *Pharm World Sci*, (30): 884-891.
21. Ulanowski, P, Jakubczyk, M and Hermanowski, T (2007), Sources of Information on Drugs Used by General Practitioners in Poland, *Value In Health*, (11) Issue 6: A367.
22. Ootom, S. Batieha, A. Hadidi, H. Hassan, M. and Al-Saudi, K (2002), Evaluation of drug use in Jordan using WHO prescribing indicators, *Eastern Mediterranean Health Journal*, (8), No. 4&5
23. المجلة العربية لدراسات الصيدلانية :العدد 10 (2006) المجلة العربية لدراسات الصيدلانية
24. المجلة العربية لدراسات الصيدلانية :العدد 10 (2006) المجلة العربية لدراسات الصيدلانية
25. المجلة العربية لدراسات الصيدلانية :العدد 10 (2002) المجلة العربية لدراسات الصيدلانية
26. المجلة العربية لدراسات الصيدلانية :العدد 10 (2006) المجلة العربية لدراسات الصيدلانية
27. Amerson, Katherine (2007), Direct-to-consumer pharmaceutical advertising in men's and women's magazines, unpublished master's thesis, Texas Tech University: Texas, USA. (Unpublished Thesis)
28. Anderson, Gail (2005), Sex and Racial Differences in pharmacological Response: where is the Evidence? *Pharmacogenetics, pharmacokinetics, and pharmacodynamics Journal of women's Health*, (14) 1: 19 – 29.
29. Phillips, Susan (2005), Defining and measuring gender: A social determinant of health whose time has come, *International Journal for Equity in Health*, (4):11 Retrieved in November 2008 from: <http://www.equityhealthj.com/content/4/1/11>

Friday 12th of July 2024 07:47:41 AM